SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Midterm election results and the prospect of a Democratic sweep dominate discussion, with traders blaming perceived regulatory and AI-spending risks for QQQs sharp volatility while others argue the outcome was priced in and the selloff is an overreaction. Strong AMD and Super Micro results also fueled optimism about AI-related tech and a possible rebound.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention around midterm election results and expectations of Democratic gains, with traders connecting a potential loss of Republican control to political risk for Trump Media. The conversation is largely bearish, though some users argue the results are routine midterm losses or anticipate a rebound.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly results beat expectations, and its stronger outlookdriven by accelerating AI data-center demandsparked a sharp after-hours rally. Bulls welcomed the growth forecast, while skeptics questioned the valuation and the sustainability of AI-driven growth amid weaker free cash flow, rising inventory, and concerns that the initial post-earnings gains could fade.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros quarterly results and raised full-year outlook, driven by strong AI-server demand, are the main focus. Many traders call the results a major beat and see the shares as undervalued, while others question thin margins, cash flow, and lingering management credibility concerns that may be weighing on the stocks muted response.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL chatter centers on sharp swings in semiconductor stocks amid concerns about an AI trade pullback, election uncertainty, and selling in chip names such as AMD, Intel, and Marvell. Traders remain divided between expecting a rebound on strong chip demand and earnings, and warning that persistent selling and leveraged-ETF decay could deepen losses.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Midterm-election uncertainty is driving volatility in Nvidia and the broader AI trade, with traders debating whether a Democratic sweep could weigh on data-center spending and AI regulation or whether the risk is already priced in. AMDs strong results are also fueling optimism that AI-chip demand remains resilient, supporting a semiconductor rebound.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

A letter from 28 HOPE-3 investigators urging FDA approval of Capricors deramiocel and defending the trial data has intensified discussion ahead of the FDA decision. Many traders see the letter as strengthening the approval case and fueling the rally, while others point to the adverse advisory-committee review and uncertainty over the FDAs interpretation of the data; claims of leaks or short covering remain speculation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp, sector-wide selloff in AI infrastructure and neocloud stocks, as traders debate whether the AI buildouts debt, funding needs and uncertain profitability justify lower valuations. Bulls call the decline an oversold, market-driven pullback and are buying dips, while bears warn that financing risks and bubble concerns could drive further losses; the latest bounce has not settled the debate.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas pullback is being tied by traders to midterm-election uncertainty, with speculation that Democratic gains could bring congressional scrutiny of Elon Musk and complicate the proposed TeslaSpaceX combination; others see merger speculation or the political outcome as potential support. The debate is compounded by criticism that Teslas valuation is hard to justify given concerns about earnings and sales, alongside short-term options volatility.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers Q3 revenue miss has intensified concerns about its early transition from bitcoin mining to AI data-center leasing, financing needs and execution. Bulls point to initial HPC lease revenue and expanded long-term contracts, while bears question whether those prospects offset near-term losses; the sharp rebound has also fueled oversold-bounce and short-squeeze speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View

Neurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.

JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View

Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.

Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates

Amneal (AMRX) delivered earnings and revenue surprises of +8.33% and +5.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Gears Up to Report Q3 Earnings: Here's What to Expect

IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.

ETON Gears Up to Report Q3 Earnings: What Can Investors Expect? 

Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

PGEN's Q3 results hinge on Papzimeos sales momentum and pipeline updates as competitive threat grows from a newly approved RRP therapy.

GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.

$AMRX Q3 &#39;26 Earnings Results &amp; Recap

Amneal increased full year 2026 net revenue guidance to $3.15B$3.25B, adjusted EBITDA to $800M$815M, and adjusted diluted EPS to $1.04$1.08; operating cash flow guidance was updated to $325M$375M.

Stocktwits

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

 Q3 '26 Earnings Results & Recap

Amneal increased full year 2026 net revenue guidance to $3.15B$3.25B, adjusted EBITDA to $800M$815M, and adjusted diluted EPS to $1.04$1.08; operating cash flow guidance was updated to $325M$375M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Amneal increased full year 2026 net revenue guidance to $3.15B$3.25B, adjusted EBITDA to $800M$815M, and adjusted diluted EPS to $1.04$1.08; operating cash flow guidance was updated to $325M$375M.

Amneal reported a GAAP loss versus prior-year income, nine-month operating cash flow of $50.31M versus $209.68M, net leverage of 3.9x versus 3.5x, and disclosed customer and product concentration risks.

Amneal reported Affordable Medicines and Specialty revenue increases, higher adjusted EBITDA and adjusted diluted EPS, and management cited new launches, a Kashiv integration proceeding well, and biosimilar growth potential.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Ipsen’s Somatuline Depot booked $983 million in U.S. sales in the year through July, according to IQVIA.&nbsp;</li><li>The agency also granted Competitive Generic Therapy status, a label meant to speed copies of drugs that still face thin competition.</li><li>For Amneal, the launch is another hard-to-make injectable in its Affordable Medicines lineup.</li></ul><p><br>Shares of Amneal Pharmaceuticals (AMRX) extended their gains after the closing bell on Friday after the company said the U.S. Food and Drug Administration (FDA) had approved its lanreotide injection and that the product would go on sale immediately.</p><p>The stock closed at $18.71, up 2.35% in regular trading, then rose another 2% after-hours to $19.17 as investors reacted to the long-awaited launch in a market worth almost $1 billion.</p><h2 class="st-heading-2">Green Light, Then An Immediate Start</h2><p>The FDA cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection. Doctors use it to tame excess growth hormone in acromegaly, slow certain gut and pancreatic neuroendocrine tumors, and ease carcinoid syndrome flare-ups. The agency also granted Competitive Generic Therapy status, a label meant to speed copies of drugs that still face thin competition. Amneal said the product is ready now. Ipsen’s brand booked $983 million in U.S. sales in the year through July, according to IQVIA.</p><p>Rivals are already on the market, such as one made by Cipla’s InvaGen unit.</p><h2 class="st-heading-2">A Date The Company Had Been Circling</h2><p>This was not a sudden win. Amneal’s public pipeline had pointed to a third-quarter 2026 decision. On the July earnings call, co-CEO Chirag Patel said the file had a formal goal date in the quarter and that some sales were already in the forecast, though conservatively.</p><p>For Amneal, the launch is another hard-to-make injectable in its Affordable Medicines lineup, made in company plants rather than farmed out. Srinivas Kone, the unit’s chief scientific officer, said the company can supply the market at scale and use the product as a growth engine.</p><h2 class="st-heading-2">How Did AMRX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AMRX stock stayed in ‘bearish’ territory over the past 24 hours, while message volume remained ‘high.’</p><p><a href="https://stocktwits.com/symbol/AMRX">AMRX stock</a> has risen 48% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/boeing-starliner-may-get-a-bigger-nasa-role-despite-leaving-crew-behind-as-space-x-looks-past-dragon-says-report/cZtHIQ2RBEf">Boeing Starliner May Get a Bigger NASA Role Despite Leaving Crew Behind As SpaceX Looks Past Dragon, Says Report</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Amneal Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.

AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.


iShares Core S&P Small-Cap ETF

Vanguard Total Stock Market ETF

Republicans keep both chambers

Republicans keep the House, lose the Senate

Republicans keep the Senate, lose the House

Democrats win both chambers

Stocktwits Polls

$AMRX $LLY $REGN exceptionally strong third-quarter earnings report driven by blockbuster demand for its GLP-1 medications.

Inspector Gadget

$AMRX $LLY $REGN GLP-1 medications are the single largest driver of Lilly's explosive financial growth.$QQQ

$AMRX reported earnings this morning before the open and beat EPS estimates: $0.26 adjusted EPS vs $0.2374 expected, according to Stock Meadow.

john

$AMRX Q3 '26 Earnings Results & Recap

Amneal increased full year 2026 net revenue guidance to $3.15B$3.25B, adjusted EBITDA to $800M$815M, and adjusted diluted EPS to $1.04$1.08; operating cash flow guidance was updated to $325M$375M.

$AMRX Under accumulation. Strong Volume with increasing price.  Looking for the next leg up from here. GLTA!

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMRX Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Fundamentals

Latest AMRX News